ERS Research Seminar

Lung Cancer Screening: from Trial to Practice

11 -12 December 2018
Barcelona, Spain

Tuesday, 11 December 2018

08.30-09.00 Registration
09.00-09.15 Introduction and Welcome
Jan van Meerbeeck and Annemie Snoeckx

Session 1 - Lung cancer screening: what do we know, what don’t we know
Chairs: Nina Bostantzoglou and Guido van Hal
09.15-09.45 Latest data of the NELSON-trial: the last step before implementation in Europe?
Harry De Koning (Netherlands)
09.45-10.15 What can we learn from the US experience? - TBC
10.15-10.30 General discussion
10.30-11.00 Coffee break

Session 2 – Targeting the hard-to-reach: one of the biggest challenges
Chairs: John Field and Annemie Snoeckx
11.00-11.20 Participation in screening: lessons learned from the past
Guido Van Hal (Belgium)
11.20-11.40 Public understanding and informed decision making: keys to a successful screening programme
David Ritchie (Belgium)
11.40-11.55 The role of patient advocacy groups in implementation
Bert van Herk (Netherlands)
11.55-12.15 How to best target the hard-to-reach? The UK-experience
Samantha Quaife (UK)
12.15-12.30 General discussion
12.30-14.00 Lunch Break
Session 3 – Broadening the scope: should we stick to only lung cancer, CT and smokers, or is there more?

*Chairs: Harry De Koning (Netherlands)*

14.00-14.30 Added value beyond lung cancer screening  
*Hans-Ulrich Kauczor (Germany)*

14.30-15.00 Who should we screen beyond (ex-) smokers  
*Jan van Meerbeeck (Belgium)*

15.00-15.30 Breathomics: an extra nose to detect lung cancer?  
*Marc van der Schee (Netherlands)*

15.30-16.00 Blood biomarkers: ready for practice?  
*John Field (UK)*

16.00-16.30 Discussion

16.30-16.45 Coffee break

16.45-17.45 Breakout sessions

Group 1: Epidemiologic implementation  
*Chairs: Guido van Hal and Harry De Koning*  
Discussion of the possible solutions, strategies and research opportunities to target the hard-to-reach population

Group 2: Technical implementation  
*Chairs: Annemie Snoeckx and Hans-Ulrich Kauczor*  
Discussion of the numerous aspects that need to be addressed before lung cancer screening can be implemented in daily practice

Group 3: Dilemma’s in lung cancer screening  
*Chairs: Jan Van Meerbeeck and Bert van Herk*

17.45-18.15 Report from break out groups and closing remarks of day 1

**Wednesday, 12 December 2018**

Session 4 – From trial to practice: concerns of different stakeholders  
*Chairs: John Field and Hans-Ulrich Kauczor*

08.30-09.00 What to do with all those pulmonary nodules: the pulmonologist’s view  
*Nina Bostantzoglou (Greece)*

09.00-09.30 How will lung cancer screening impact our daily practice? A radiologist’s view  
*Annemie Snoeckx (Belgium)*
09.30-10.00 The surgeon’s point of view  
Anna Elisabeth Frick (Belgium)

10.00-10.30 General discussion

10.30-11.00 Coffee break

11.00-11.30 Artificial Intelligence: an extra clinician we can not ignore  
Bram Van Ginneken (Netherlands)

11.30-12.00 Report of ongoing trials  
John Field (UK)

12.00-12.30 ERS-ESR White Paper on Lung Cancer Screening  
Hans-Ulrich Kauczor (Germany)

12.30-13.00 Remarks, conclusions and action points

13.00 Lunch and farewell